China focus: BioGaia's new launch, Herbalife's esports initiatives, Lianhua Qingwen boom in the spotlight
Bone health probiotic: BioGaia to launch Osfortis in China via cross-border e-commerce
BioGaia is launching its bone health probiotic, Osfortis, into China via cross-border e-commerce (CBEC) channel – its first Asian market for the product.
Osfortis contains the proprietary lactic acid bacterium Limosilactobacillus reuteri ATCC PTA 6475 and vitamin D3 for the maintenance of normal bone health.
This will add on to existing range of products available in China, including its flagship product Protectis baby drops for infant colic, oral health probiotics Prodentis, and Gastrus, a probiotic for gut health.
China’s e-sports nutrition: Herbalife on big opportunities in fitness, sleep and stress relief segments
Herbalife says there are vast opportunities to tap into the fitness, sleep, and stress relief nutritional needs of China’s booming e-sports industry.
The company has been involved in a number of e-sports initiatives since last year, such as being the primary sponsor and official nutrition partner of the Guangzhou Charge team in the 2020 – 2022 season of Overwatch League.
Last month, it also opened the Herbalife Nutrition X Nenking eSports Center in Greater Bay Area International Sports and Cultural Center (GBA Center) located in Foshan.
Light to moderate intake of raw garlic linked with CVD benefits among Chinese adults – Study
A light-to-moderate consumption of raw garlic, one to three times per week, appears to provide heart health benefits among Chinese adults, according to a new population study.
Intake was associated with a lower prevalence of thickened carotid intima-media thickness (cIMT).
cIMT is an early marker of atherosclerosis (plaque build-up), and predictor of cardiovascular disease (CVD) risk, morbidity, and mortality.
International boom: Yiling Pharmaceutical sees overseas revenue soar amid COVID-19 interest in Lianhua Qingwen botanical
Yiling Pharmaceutical, the company behind TCM/dietary supplement product Lianhua Qingwen, said revenue from its overseas market was up 918.37 per cent in FY2020, after the product was officially recognised by the China authorities as a COVID-19 standard therapy for mild symptoms such as fever and cough.
Yiling Pharmaceutical’s growth in the overseas markets last year started from a small base of RMB$29m (US$4.56m) in FY2019.
This grew to RMB$304m (US$46m) last year. Revenue from the overseas markets now occupies 3.46 per cent of the company’s total revenue.
Functional gummy growth: China’s BUFFX gears up for new product launches with ambitious US$15m sales goal
China’s functional food start-up BUFFX is gearing up to launch 16 new products as part of its target to achieve RMB100 million (US$15m) in sales this year.
BUFFX first entered the market in late 2020, with seven gummy supplements, targeting energy, sleep, eye, immunity, digestion and liver health.
Its sleep supplement containing GABA has been the top selling product in the ‘sleep’ category on e-commerce site Tmall since October 2020.